secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2026-11-10T22:30:46+00:00
Accession:  0001193125-26-455789
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Spero Therapeutics appoints William Ho to board as Patrick Vink resigns
-----------------------------------------------------------------------

- Patrick Vink, M.D., resigned from Spero's board effective Nov. 10, 2026, including roles as Nominating and Corporate Governance Committee chair and Compensation Committee member.
- The company said Vink's resignation was not due to any dispute or disagreement and thanked him for 11 years of service.
- William Ho, M.D., Ph.D., was appointed Class II director effective Nov. 10, 2026, and will serve on the Development Committee.
- Ho will receive a $40,000 annual board retainer, $5,000 committee retainer and an option for 100,000 shares vesting monthly over one year.
- Ho was RAPT Therapeutics' chief medical officer from 2015 to December 2025; the filing cites RAPT's $2.2 billion acquisition by GSK finalized in March 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526455789/0001193125-26-455789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526455789/d196561d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer